Soluble CD83 Biomarker: NMOSD & MOGAD Diagnosis
New Biomarker Shows Promise in distinguishing MOGAD from MS,Predicting Disease Course
Table of Contents
For years,differentiating between Myelin Oligodendrocyte glycoprotein Antibody-Associated Disease (MOGAD) and Multiple Sclerosis (MS) has been a diagnostic challenge. Both autoimmune disorders attack the central nervous system, leading to similar symptoms like vision loss, weakness, and numbness.Though, recent research published in Frontiers in Immunology offers a meaningful breakthrough: a biomarker called soluble CD83 (sCD83) shows remarkable potential in not only distinguishing between the two conditions but also predicting disease severity and response to treatment.
The Diagnostic Dilemma: MOGAD vs.MS
MOGAD and MS are both demyelinating diseases, meaning they damage the protective myelin sheath surrounding nerve fibers. This damage disrupts communication between the brain and body, resulting in a wide range of neurological symptoms. While both can present similarly, understanding the underlying differences is crucial for accurate diagnosis and tailored treatment.
Misdiagnosis can lead to inappropriate therapies, possibly hindering a patient’s progress and quality of life. Traditionally, diagnosis relies on clinical presentation, MRI findings, and cerebrospinal fluid (CSF) analysis. However, these methods aren’t always definitive, notably in the early stages of the disease. This is where sCD83 steps in as a potential game-changer.
sCD83: A New Window into Autoimmune Demyelinating Diseases
The Mayo Clinic-led study investigated sCD83 levels in the CSF and serum of patients with MOGAD, Neuromyelitis Optica Spectrum Disorder (NMOSD), other noninflammatory neurological disorders, and healthy controls. Researchers discovered striking differences.Key Findings:
Lower sCD83 in NMOSD & MOGAD: Patients with NMOSD had significantly lower sCD83 levels in their CSF compared to both MOGAD and other neurological conditions. MOGAD patients also showed lower levels than those with other noninflammatory disorders.
Relapsing Disease & sCD83: Interestingly,sCD83 levels were even lower in patients experiencing relapsing forms of MOGAD compared to those with a monophasic (single-episode) presentation. This suggests sCD83 could be a predictor of future relapses.
sCD83 & Brain Health: A strong positive correlation was found between serum sCD83 levels and normalized total brain volume in MOGAD patients. Higher sCD83 appeared to be associated with better brain preservation.
sCD83 & visual Function: In NMOSD patients with optic neuritis (inflammation of the optic nerve),lower sCD83 levels correlated with worse visual evoked potential (VEP) scores – a measure of visual pathway function. IVIG Boosts sCD83: Intravenous immunoglobulin (IVIG), a common treatment for autoimmune disorders, was shown to significantly increase sCD83 concentrations in both MOGAD and NMOSD patients. This suggests IVIG may be working, in part, by restoring sCD83 levels.
What Does This Mean for You?
These findings are incredibly promising. sCD83 isn’t just a marker of disease presence; it appears to reflect disease activity, potential for relapse, and even treatment response.
Here’s how this could impact your care:
Earlier, More Accurate Diagnosis: sCD83 testing could help doctors differentiate between MOGAD and MS earlier in the disease course, leading to more appropriate treatment strategies.
Personalized Treatment: Monitoring sCD83 levels could help tailor treatment plans to individual patients. For example, those with low sCD83 might benefit from more aggressive therapies or closer monitoring.
Predicting relapses: Tracking sCD83 levels could potentially identify patients at higher risk of relapse, allowing for proactive intervention.
* Assessing Treatment Effectiveness: Changes in sCD83 levels after treatment could provide valuable insights into how well a therapy is working.
The Road Ahead: Further Research Needed
While these results are exciting, the researchers emphasize the need for further investigation. The study involved a relatively small number of participants